# Benchling

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/benchling

- Industry: Software
- Headquarters: San Francisco, US
- Website: www.benchling.com
- Total disclosed funding: $418M
- Latest round: Series F (Oct 20, 2021)
- Investors on record: 20

## About

Founded in 2012 in San Francisco, CA, Benchling, Inc. operates as a biotechnology software company, providing cloud-based solutions that facilitate research and development for scientists across various fields. Benchling, Inc. has raised Series F in October 2021 which was co-led by Altimeter Capital Management and Franklin Templeton. The company is currently valued at USD 5.66 billion. Benchling offers a comprehensive suite of cloud-based solutions tailored for the biotechnology research and development sector. The company's core products include Benchling Bioresearch, Benchling Bioprocess, and Benchling In Vivo, enabling scientists to plan, record, and share experiments seamlessly through an integrated electronic lab notebook (ELN). These solutions automate workflows, capture scientific data efficiently, and facilitate collaboration. Leveraging artificial intelligence, Benchling enhances productivity and accelerates data analysis across applications, including biomolecular research and gene therapy. Over 200,000 scientists, including startups and prominent biopharmaceutical companies in North America, Europe, and Asia, utilize Benchling’s platforms for research efficiency. Benchling's revenue model is primarily based on subscription services, where customers access its suite of products through tiered pricing plans. Clients typically engage in annual subscriptions that vary based on their operational scale and required tools, including features from Benchling Bioresearch and Benchling Insights. The company also provides customer success packages for tailored support, enhancing the user experience. Benchling's partnerships with leading biopharmaceutical firms and research institutions reinforce its market reputation, facilitating robust B2B relationships and long-term collaborations that adapt its capabilities to clients' evolving scientific needs. The company aims to introduce new products designed to enhance its offerings for biotechnology research. Benchling is strategically targeting expansion into new markets, with plans to enhance its presence in Europe, the Middle East, and Africa by leveraging the recent funding to support these initiatives.

## Funding rounds

- Series F, Oct 20, 2021, $105M — Tiger Global Management, Lone Pine Capital, Altimeter Capital, Franklin Templeton
- Series E, Mar 12, 2021, $200M — Benchmark, Menlo Ventures, Hong Shan, Spark Capital, Lux Capital, Alkeon Capital Management, Thrive Capital, Lead Edge Capital, ICONIQ Capital, Altimeter Capital, Byers Capital
- Series D, Mar 24, 2020, $51M — Benchmark, Menlo Ventures, Spark Capital, Lux Capital, Alkeon Capital Management, Thrive Capital, ICONIQ Capital
- Series C, Apr 16, 2019, $35M — Benchmark, Menlo Ventures, Thrive Capital, Y Combinator, Lead Edge Capital
- Series B, Mar 23, 2018, $16M — Benchmark, F-Prime Capital, Thrive Capital
- Series A, Apr 18, 2016, $7M — Andreessen Horowitz, Thrive Capital
- Seed, Feb 6, 2015, $5.1M — Founders Fund, Andreessen Horowitz, SV Angel, Thrive Capital, Y Combinator, Rock Health

## Investors

- Founders Fund (https://capitalatlas.ai/funds/founders-fund) — Seed
- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Seed, Series A
- SV Angel (https://capitalatlas.ai/funds/sv-angel) — Seed
- Thrive Capital (https://capitalatlas.ai/funds/thrive-capital) — Seed, Series A, Series B, Series C, Series D, Series E
- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed, Series C
- Rock Health (https://capitalatlas.ai/funds/rock-health) — Seed
- Benchmark (https://capitalatlas.ai/funds/benchmark) — Series B, Series C, Series D, Series E
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series B
- Menlo Ventures (https://capitalatlas.ai/funds/menlo-ventures) — Series C, Series D, Series E
- Lead Edge Capital (https://capitalatlas.ai/funds/lead-edge-capital) — Series C, Series E
- Spark Capital — Series D, Series E
- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Series D, Series E
- Alkeon Capital Management (https://capitalatlas.ai/funds/alkeon-capital-management) — Series D, Series E
- ICONIQ Capital (https://capitalatlas.ai/funds/iconiq-capital) — Series D, Series E
- Hong Shan — Series E
- Altimeter Capital (https://capitalatlas.ai/funds/altimeter-capital) — Series E, Series F
- Byers Capital (https://capitalatlas.ai/funds/byers-capital) — Series E
- Tiger Global Management (https://capitalatlas.ai/funds/tiger-global-management) — Series F
- Lone Pine Capital — Series F
- Franklin Templeton (https://capitalatlas.ai/funds/franklin-templeton) — Series F